Guggenheim analyst Vamil Divan raised the firm’s price target on AbbVie (ABBV) to $249 from $242 and keeps a Buy rating on the shares. The firm has “modestly adjusted” quarterly estimates based on its latest review of IQVIA script data and its recent check-in with the investor relations team ahead of the company’s Q1 earnings release on April 29.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Trump Trade: AbbVie sues White House over discount drug program
- Three Options Trades That Could Return Up To 841%
- AbbVie sues White House over discount drug program, Axios says
- AbbVie price target lowered to $240 from $250 at Cantor Fitzgerald
- AbbVie’s Real‑World Parkinson’s Study in Belgium: What Investors Should Watch